Top Tech Companies (50)
Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. We've partnered with some of the world’s largest pharmaceutical and agrochemical c
Aizon is an AI software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP compliant manner with end-to-end data integrity.
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.
ZBiotics, a San Francisco-based DTC company funded by Y Combinator and Khosla Venture, uses genetic engineering to create products for healthy adults who choose to use the power of science to enhance their daily lives. Our flagship product is a probiotic drink that breaks down acetaldehyde, a toxic byproduct of alcohol most responsible for rough mornings after drinking.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
.png)
Helix is a rapidly growing startup focused on personal genomics. Helix has a simple but powerful mission: to empower every person to improve their life through DNA. We’re creating an ecosystem where people can explore diverse and uniquely personalized applications provided by high-quality partners.
Specific Diagnostics' Impact on Sepsis With Sepsis, time is of the essence. Specific Diagnostic’s Reveal Rapid AST System produces AST results within an average of 5 hours directly from blood culture. This allows the patient’s care team to switch them to the optimal antibiotic therapy up to 2 days sooner than with traditional AST methods to ensure the bacterial infection is treated and doesn’t cause further harm.
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and pioneers in chemistry, technology, and the life sciences, with a deep bench of expertise in drug development and commercialization spanning from large pharma to biotech innovators. The company is based in Sunnyvale, CA.
Gladstone's mission is to drive a new era of discovery in disease-oriented science and to mentor tomorrow’s leaders in an inspiring and diverse environment. Although Gladstone shares traits with other top life science organizations, we pride ourselves on taking uncommon scientific paths to overcoming disease. Our investigators are selected to become authorities in leading or creating new fields, and we work to provide them with resources to explore bold new thoughts, form effective scientific teams, and create or master emerging research technologies that accelerate progress—Gladstone’s special recipe for success that has yielded some of the most important biomedical advances of our time. Our three disease-focused institutes constitute the core of our discovery engine, but do not operate in isolation. We are seizing unprecedented opportunities for “convergence”—defined as the blending of intellectual and physical assets from multiple scientific disciplines and fields to speed the discovery process in our attack on unsolved health problems that affect almost every human family.
Spring Discovery is accelerating the discovery of therapies for aging. By targeting the biological processes of aging itself, we aim to uncover new therapies for the diseases of old age — from cardiovascular to neurodegenerative disease — and increase our healthy lifespans. We've built a machine learning platform to accelerate experimentation for discovering such therapies.
iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias. We have created a unique platform, ZIO by iRhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
64x Bio is transforming the future of cell and gene therapy manufacturing with high throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics
BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all. Our patent-pending molecular counter platform is the only technology platform that can accurately count the DNA molecules at the single-count level.
Pattern Ag is developing a recommendation and product discovery platform centered around a deep understanding of soil. We are leveraging advances in genomics, robotics, and high-resolution agronomic data to build this knowledge, in service of improving farm profitability
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products
Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Based on an innovative scientific approach and industry leading internal manufacturing capability and expertise, we are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy. The company leverages the power of lysine-based covalency across the disease spectrum to develop both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Many of Terremoto’s founders helped establish this emergent area of science, with the intent to broaden the number of tractable targets and deliver medicines with superior therapeutic benefit. Terremoto is supported by leading investors OrbiMed and Third Rock Ventures.
